EGFR and neoplasm: Although TKIs have dramatically changed the management of metastatic non-small cell lung cancer (NSCLC)5,8,44, the detection of a driver EGFR mutation in tumor tissue or ctDNA is necessary but insufficient for predicting response6,12.